Second-generation prophylactic HPV vaccines: successes and challenges.
Second-generation prophylactic HPV vaccines: successes and challenges.
复制标题
DOI：
10.1586/14760584.2014.865523
复制
发表时间：
2014-02
影响因子：
6.2
通讯作者：
Chackerian B
中科院分区：
文献类型：
--
作者：
Tyler M;Tumban E;Chackerian B
人乳头瘤病毒（HPV）作为宫颈癌的致病因素的作用导致了HPV疫苗Gardasil和Cervarix的开发。这些疫苗有效地预防与70%的宫颈癌病例相关的两种HPV类型。尽管取得了这一成功，研究人员仍在继续开发第二代HPV疫苗，以预防更多的HPV类型，并允许发展中国家增加接种。虽然基于当前技术的重新配制的疫苗目前正在临床试验中，但另一种策略包括靶向HPV L2次要衣壳蛋白中的高度保守表位。靶向L2的疫苗诱导广泛中和抗体，能够阻断各种HPV类型的感染。已经开发了几种疫苗设计以优化L2表位向免疫系统的展示并降低制造和分配的成本。基于L2的疫苗作为潜在的下一代HPV疫苗显示出相当大的前景。
The role of human papillomavirus (HPV) as the causative factor in cervical cancer has led to the development of the HPV vaccines Gardasil and Cervarix. These vaccines effectively protect against two HPV types associated with 70% of cervical cancer cases. Despite this success, researchers continue to develop second generation HPV vaccines to protect against more HPV types and allow increased uptake in developing countries. While a reformulated vaccine based on the current technology is currently in clinical trials, another strategy consists of targeting highly conserved epitopes in the minor capsid protein of HPV, L2. Vaccines targeting L2 induce broadly neutralizing antibodies, capable of blocking infection by a wide range of HPV types. Several vaccine designs have been developed to optimize the display of L2 epitopes to the immune system and to reduce the cost of manufacture and distribution. L2-based vaccines show considerable promise as a potential next-generation HPV vaccine.
登录
查看更多内容
影响因子：
51.1
作者：
de Sanjose, Silvia;Quint, Wim G. V.;Xavier Bosch, F.
通讯作者：
Xavier Bosch, F.
影响因子：
--
作者：
Day, Patricia M.;Pang, Yuk-Ying S.;Schiller, John T.
通讯作者：
Schiller, John T.
影响因子：
3.8
作者：
CAMPO, MS;GRINDLAY, GJ;JARRETT, WFH
通讯作者：
JARRETT, WFH
影响因子：
5.4
作者：
Buck, Christopher B.;Cheng, Naiqian;Trus, Benes L.
通讯作者：
Trus, Benes L.
影响因子：
3.8
作者：
de Oliveira, Cristina Mendes;Tavares Guerreiro Fregnani, Jose Humberto;Levi, Jose Eduardo
通讯作者：
Levi, Jose Eduardo